Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SurgiLight seeks US trial for presbyopia laser:

This article was originally published in Clinica

Executive Summary

SurgiLight has filed an application with the US FDA to start a multicentre, 350-patient trial of it laser treatment for presbyopia, a vision problem believed to affect around 90 million people in the US over the age of 40. Data from four sites outside the US have shown that the company's OptiVision system reversed presbyopia in nine of every 10 eyes of more than 100 eyes treated, with the results extending up to one year after surgery, says Orlando, Florida-based SurgiLight.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073991

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel